Products for Research Use Only

PF-00835231

CAT: 0804-HY-137048-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-137048-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
PF-00835231 is a CoV-2 cysteine 3C-like protease (3CLpro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CLpro, respectively. PF-00835231 is developed for the research of anti-SARS-CoV-2/COVID-19. PF-00835231 can inhibit cell infections and also suppress infections in animal models[1][2][3].
CAS Number
870153-29-0
UNSPSC
12352005
Hazard Statement
H302, H319, H332, H372, H400
Target
HCV; HIV; SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/pf-00835231.html
Concentration
10mM
Purity
99.31
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
O=C(C(N1)=CC2=C1C=CC=C2OC)N[C@H](C(N[C@@H](C[C@H]3C(NCC3)=O)C(CO)=O)=O)CC(C)C
Molecular Formula
C24H32N4O6
Molecular Weight
472.53
Precautions
H302, H319, H332, H372, H400
References & Citations
[1]Robert L Hoffman, et al. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19. J Med Chem. 2020 Nov 12;63 (21) :12725-12747.|[2]de Vries M, et al. A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19. bioRxiv [Preprint]. 2021 Feb 19:2020.08.28.272880.|[3]Wujun Chen, wt al. Review of preclinical data of PF-07304814 and its active metabolite derivatives against SARS-CoV-2 infection. Front Pharmacol. 2022 Nov 11:13:1035969.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HIV-1